News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
104,377 Results
Type
Article (6488)
Company Profile (12)
Press Release (97877)
Section
Business (41528)
Career Advice (381)
Deals (7382)
Drug Delivery (53)
Drug Development (9968)
Employer Resources (33)
FDA (1776)
Job Trends (1954)
News (60145)
Policy (4389)
Tag
Academia (277)
Alliances (6017)
Alzheimer's disease (158)
Approvals (1768)
Artificial intelligence (31)
Bankruptcy (67)
Best Places to Work (1550)
Breast cancer (31)
Cancer (203)
Cardiovascular disease (27)
Career advice (326)
Cell therapy (56)
Clinical research (7846)
Collaboration (90)
COVID-19 (345)
C-suite (48)
Data (185)
Diabetes (94)
Diagnostics (855)
Drug pricing (47)
Earnings (17272)
Employer resources (31)
Events (11491)
Executive appointments (184)
FDA (1890)
Funding (105)
Gene therapy (37)
GLP-1 (425)
Government (644)
Healthcare (3218)
Infectious disease (362)
Inflammatory bowel disease (28)
Interviews (43)
IPO (3148)
Job creations (437)
Job search strategy (295)
Layoffs (67)
Legal (1111)
Lung cancer (28)
Manufacturing (65)
Medical device (2386)
Medtech (2387)
Mergers & acquisitions (4308)
Metabolic disorders (280)
Neuroscience (212)
NextGen Class of 2024 (1017)
Non-profit (452)
Northern California (329)
Obesity (181)
Opinion (54)
Patents (25)
People (16750)
Phase I (2464)
Phase II (3609)
Phase III (2786)
Pipeline (137)
Podcasts (29)
Policy (31)
Postmarket research (211)
Preclinical (894)
Radiopharmaceuticals (63)
Rare diseases (53)
Real estate (610)
Regulatory (2906)
Research institute (316)
Resumes & cover letters (51)
Series A (25)
Southern California (232)
Startups (612)
The Weekly (26)
United States (2576)
Vaccines (83)
Weight loss (183)
Date
Today (4)
Last 7 days (21)
Last 30 days (389)
Last 365 days (6740)
2025 (5)
2024 (6797)
2023 (7097)
2022 (9815)
2021 (9961)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (122)
Arizona (23)
Asia (6959)
Australia (1122)
California (656)
Canada (322)
China (60)
Colorado (54)
Connecticut (33)
Europe (15820)
Florida (101)
Georgia (25)
Illinois (47)
Indiana (64)
Maryland (148)
Massachusetts (406)
Minnesota (33)
New Jersey (322)
New York (145)
North Carolina (145)
Northern California (329)
Ohio (28)
Pennsylvania (133)
South America (187)
Southern California (232)
Texas (98)
Washington State (37)
104,377 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
December 19, 2024
·
1 min read
Press Releases
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
December 16, 2024
·
2 min read
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Novo Holdings Completes Acquisition of Catalent
December 18, 2024
·
4 min read
Press Releases
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
December 9, 2024
·
1 min read
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.
December 18, 2024
·
2 min read
·
Annalee Armstrong
Manufacturing
Novo Deepens Denmark Commitment With $1.2B Rare Disease Production Facility
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which analysts expect will help the pharma expand its production capacity.
December 16, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.
December 20, 2024
·
3 min read
·
Annalee Armstrong
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
1 of 10,438
Next
